Table 2.
Pharmacokinetic parameters obtained alter the oral administration of 100:25 mg/kg levodopa/carbidopa in the three groups studied (initial situation; treatment with Plantago ovata husk and treatment with placebo) to 18 Parkinson patients
| Initial situation | Treatment A (Plantago ovata husk) | Treatment B (Placebo) | ||||
|---|---|---|---|---|---|---|
| Parameters | Mean ± SD | CV(%) | Mean ± SD | CV(%) | Mean ± SD | CV(%) |
| t max (min) | 35.83 ± 16.91 | 47.20 | 39.72 ± 17.19 | 43.28 | 36.17 ± 26.30 | 59.56 |
| C max (ng/ml) | 603.2 ± 242.4 | 40.19 | 547.8 ± 192.6 | 35.16 | 612.0 ± 176.6 | 28.86 |
| AUC (μg.min/ml) | 62.87 ± 15.77 | 25.09 | 64.47 ± 15.27 | 23.69 | 65.10 ± 14.33 | 22.01 |
| λ (min -1 ) | 0.0096 ± 0.0018 | 18.87 | 0.0088 ± 0.0020 | 22.54 | 0.0097 ± 0.0018 | 18.40 |
| V ss /F (l) | 0.1845 ± 0.0628 | 34.05 | 0.1929 ± 0.0521 | 27.04 | 0.1699 ± 0.0468 | 27.58 |
| Cl/F (l/min) | 0.0017 ± 0.0004 | 25.98 | 0.0016 ± 0.0004 | 23.89 | 0.0016 ± 0.0004 | 22.52 |
| AUMC (μg.min 2 /ml) | 7881.7 ± 2630.3 | 33.37 | 8313.7 ± 2284.4 | 27.48 | 8327.1 ± 2651.9 | 31.85 |
| MRT (min) | 125.1 ± 29.9 | 23.93 | 129.2 ± 21.7 | 16.78 | 126.6 ± 24.2 | 19.13 |
| C min (ng/ml) | 6.02 ± 3.41 | 56.70 | 6.31 ± 7.10 | 112.58 | 7.34 ± 7.98 | 108.71 |
| t 1/2λ (min) | 75.2 ± 16.0 | 21.27 | 81.9 ± 15.3 | 18.70 | 74.0 ± 16.9 | 22.86 |